AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized dynamic posturography
Description: Evaluation of dynamic postural control
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video Head Impulse Test
Description: Evaluation of vertigo and the vestibular organ
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometer
Description: Evaluation of gait pattern
Study NCT05241964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: 4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
Study NCT05782049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound of the salivary glands
Description: Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes.
Study NCT05782049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of salivary flow
Description: Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
Study NCT05782049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A Schirmer test
Description: A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
Study NCT05079022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib at 80mg dose will be administered orally once daily.
Study NCT05280418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tezepelumab
Description: Monoclonal antibody designed for the treatment asthma.
Study NCT05280418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo.
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib Phosphate
Description: Given PO
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05514912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05273632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Study NCT05273632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
Study NCT05009303 — intervention group
Intervention type: DEVICE
Intervention: OneStep Smartphone App and C-Mill Treadmill
Description: OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
Study NCT05543850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal closed-loop control
Description: During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
Study NCT05543850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop control
Description: During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
Study NCT06211660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-based AR training system
Description: Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
Study NCT06211660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand scanner and Video training
Description: Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
Study NCT06576882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
Study NCT05685459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard patient simulation model
Description: Nursing students were trained with a standard patient simulation model for position and communication skills education.
Study NCT05323539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating Thyroid Volumes by ultrasonography
Description: The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
Study NCT05488626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
Study NCT05488626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Adaptive Radiotherapy
Description: Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
Study NCT05488626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concomitant chemotherapy per NCCN or other national guidelines.
Study NCT05488626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Concomitant chemotherapy per NCCN or other national guidelines.
Study NCT05488626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Adjuvant immunotherapy per national or institutional guidelines.
Study NCT05488626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Adjuvant immunotherapy per national or institutional guidelines.
Study NCT04631263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Injectable gel. Chin correction and augmentation for retrusion
Study NCT05821738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: administered orally
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
Study NCT05524974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
Study NCT04779138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Willingness and Uptake of COVID-19 Vaccination
Description: Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
Study NCT04941040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid free anesthetics
Description: Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h
Study NCT04941040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics
Description: Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
Study NCT06268158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye patch
Description: The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
Study NCT06579898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training
Description: A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.
Study NCT06054659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Time Continuous Glucose Monitoring (rt-CGM)
Description: Participants randomized to rt-CGM will have CGM placed prior to hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will CGM devices but subjects may use their own glucometer for FBG testing as needed including for CGM calibration.
Study NCT06054659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fingerstick blood glucose (FBG) monitoring
Description: Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
Study NCT06054659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingerstick blood glucose (FBG) monitoring
Description: Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
Study NCT06054659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
Study NCT06054659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
Study NCT05167266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
Study NCT05167266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
Study NCT04775914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI + Ischemic conditioning
Description: IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
Study NCT04775914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI + Ischemic conditioning
Description: IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
Study NCT04775914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent with ultrasound
Description: IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
Study NCT04775914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent with ultrasound
Description: IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip strength
Description: Evaluation of muscle strength
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorbtimetry scan
Description: Evaluation of body composition
Study NCT06185933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Spray
Description: Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
Study NCT06185933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Viscous+Lidocane spray
Description: Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
Study NCT04873648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric reduced -intermitted fasting diet
Description: obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
Study NCT05389566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Force Plate Platform
Description: Evaluation of balance while standing still
Study NCT04873648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily calorie restriction
Description: obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
Study NCT04873648 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
Study NCT06184828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: The transfusion of whole blood units
Study NCT06184828 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood components transfusion
Description: The transfusion of blood components units rather than whole blood
Study NCT05947929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic excise
Description: the treadmill exercises three times a week for 12 weeks) based on the Following protocol: Intensity exercise: determined by karvonen formula: Exercise heart rate = \[(A-B) × desired intensity\] + B \[A represents maximum heart rate (220-age) and B for resting heart rate (average of three measurements)\]. The desired intensity will be at 50- 70%. Heart rate was measured by pulse-meter to detect pulse rate before exercise (Resting HR)\].
Study NCT05947929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: the acupuncture needles will be inserted through the adhesive pads. The acupuncture needles used in the study are 40 mm in length and 0.30 mm in diameter and manufactured by Suzhou Hwato Medical Instruments Co. Ltd (Suzhou, China). The following acupoints will be used: DU20 (Baihui), ST36 (Zusanli), ST37 (Shangjuxu), SP6 (Sanyinjiao), ST25 (Tianshu), and LR3 (Taichong).
Study NCT05806749 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donor CD34+, CD3+. and belumosudil
Description: Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24.
Study NCT06489873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)
Description: Each participant will be assigned to t a LZF supplement daily for six months
Study NCT06489873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Each participant will be assigned to take a placebo supplement daily for six months
Study NCT05609084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Patients will connect on an interface to pratice speech therapy
Study NCT05609084 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Speech therapy assessment
Description: Patients will be followed by an speech therapist